Chronic lymphocytic leukemia (CLL) is characterized by the expansion of monoclonal, mature CD5+/CD23+ B cells in the peripheral blood (PB) [1], secondary lymphoid tissues, and the bone marrow (BM).In this microenvironment CLL cells receive survival, proliferation and drug resistance signals from accessory cells and soluble factors [2]. The gene discussed is FCER2; the disease is B-cell chronic lymphocytic leukemia.